Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (12)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Zeuli, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zeuli, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 12:1737-1741, 2001
© 2001 European Society for Medical Oncology

research-article

Capecitabine and oxaliplatin in advanced colorectal cancer: A dose-finding study

M. Zeuli1,, F. Di Costanzo2, A. Sdrobolini2, S. Gasperoni2, F. P. Paoloni1, A. Carpi3, L. Moscetti4, R. Cherubini5, F. Cognetti1 and on behalf of Gruppo Oncologico Italiano per la Ricerca Clinica (GOIRC) and Gruppo Oncologico Laziale (GOL)

1 Department of Medical Oncology A. Regina Elena Cancer Institute Rome
2Department of Medical Oncology, Azienda Ospedaliera S Maria Terni
3Department of Medical Oncology, Arcispedale S. Maria Nuova Reggio Emilia
4Department of Medical Oncology, Universita ‘La Sapienza’ Rome
5Department of Medical Oncology, Azienda Ospedaliera Perugia, Italy

M. Zeuli, MD, Oncologia Medica A, Istituto Regina Elena - Polo Oncologico, Via Elio Chianesi n 53, 00144 Rome, Italy, E-mail: massimozeuli{at}tiscalinet.it

Purpose: Capecitabine and oxaliplatin are both active anti-cancer agents in the treatment of patients with advanced colorectal cancer (ACRC). The aim of this dose-finding trial was to determine the maximum-tolerated dose (MTD), the dose-limiting toxicities (DLTs) and the activity of the combination in patients with advanced colorectal cancer.

Patients and methods: Twenty-five chemotherapy-pretreated patients received the combination of capecitabine and oxaliplatin. Capecitabine was administered orally twice a day continuously for 14 days in doses ranging from 1650 to 2500 mg/m2/d, and oxaliplatin was administered as a two-hour infusion on day 1 using dose, ranges from 100 to 130 mg/m2 repeated every three weeks.

Results: Twenty-five patients were assessable for toxicity, and DLTs were diarrhea (grade ≥ 3: 27%) and stomatitis (grade ≥3: 9%) at dose level VI. Dose level V (capecitabine 2500 mg/m2 and oxaliplatin 120 mg/m2) was found to be the MTD. Hematological toxicity was minimal, overall neuro-toxicity (grade 1–4) was 27% with 1% grade 3–4. A global response rate was 17% (95% confidence interval (95% Cl): 2%–32%) and the median overall survival was 12 months.

Conclusion: The recommended dose for further phase II studies is capecitabine 2500 mg/m2/d with intermittent schedule and oxaliplatin 120 mg/m2 every three weeks. The toxicities were mainly gastrointestinal: diarrhea, stomatitis and vomiting. This combination should be studied in phase II trials in advanced colorectal.

capecitabine, colorectal cancer, dose-finding, oxaliplatin


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
M. Zeuli, C. Nardoni, M. S. Pino, T. Gamucci, A. Gabriele, V. Ferraresi, D. Giannarelli, and F. Cognetti
Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer
Ann. Onc., September 1, 2003; 14(9): 1378 - 1382.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. Scheithauer, G. V. Kornek, M. Raderer, B. Schull, K. Schmid, E. Kovats, B. Schneeweiss, F. Lang, A. Lenauer, and D. Depisch
Randomized Multicenter Phase II Trial of Two Different Schedules of Capecitabine Plus Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
J. Clin. Oncol., April 1, 2003; 21(7): 1307 - 1312.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. Schmelz, C. Lersch, J. L. Grem, T. Lehky, R. Thomas, M. Quinn, and M. K. Floeter
Acute Oxaliplatin-Induced Peripheral-Nerve Hyperexcitability
J. Clin. Oncol., August 15, 2002; 20(16): 3561 - 3562.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.